Biomarkers /
IRF4
Overview
Interferon regulatory factor 4 (IRF4) is a gene that encodes a transcription factor protein that functions as a regulator of interferons and interferon-inducible genes. The protein is also a negative regulator of Toll-like-receptor (TLR) signaling. Fusions, missense mutations, nonsense mutations, and silent mutations are observed in cancers such as hematopoietic and lymphoid cancers, intestinal cancer, and ovarian cancer.
IRF4 is altered in 1.34% of all cancers with colon adenocarcinoma, lung adenocarcinoma, breast invasive ductal carcinoma, diffuse large B-cell lymphoma, not otherwise specified, and cutaneous melanoma having the greatest prevalence of alterations [3].
The most common alterations in IRF4 are IRF4 Loss (0.28%), IRF4 Amplification (0.25%), IRF4 C99R (0.02%), IRF4 D429N (0.01%), and IRF4 R8Q (0.02%) [3].
Clinical Trials
Significance of IRF4 in Diseases
B-Cell Lymphoma, Unclassifiable, With Features Intermediate Between Diffuse Large B-Cell Lymphoma And Classical Hodgkin Lymphoma +
References
1. Hart R and Prlic A. Universal Transcript Archive Repository. Version uta_20180821. San Francisco CA: Github;2015. https://github.com/biocommons/uta
2. The UniProt Consortium. UniProt: a worldwide hub of protein knowledge. Nucleic Acids Research. 2019;47:D506-D515.
3. The AACR Project GENIE Consortium. AACR Project GENIE: powering precision medicine through an international consortium. Cancer Discovery. 2017;7(8):818-831. Dataset Version 8. This dataset does not represent the totality of the genetic landscape; see paper for more information.
4. All assertions and clinical trial landscape data are curated from primary sources. You can read more about the curation process here.